MRM Health’s ulcerative colitis treatment receives FDA Investigational New Drug clearance
January 27, 2026FDA, Gastrointestinal tract, MRM Health, ulcerative colitis
Microbial Resource Management (MRM) Health has announced that its lead programme, MH002, has received Investigational New Drug (IND) clearance from …
Crystalys Therapeutics appoints Justin Thacker as Chief Financial Officer
January 27, 2026Crystalys Therapeutics, chief financial officer
Crystalys Therapeutics has announced the appointment of Justin Thacker as Chief Financial Officer (CFO). Thacker has spent over 20 years …
Rentschler Biopharma appoints Uwe Buecheler as interim CEO
January 26, 2026Rentschler Biopharma, interim CEO
Rentschler Biopharma, a contract development and manufacturing organisation (CDMO) specialising in biopharmaceutical products, has announced the appointment of Uwe Buecheler …
Sandoz’ Ondibta receives European Commission approval for diabetes
January 26, 2026Research and Development Diabetes, Ondibta, Sandoz
Sandoz has announced that its Ondibta (insulin glargine) has received approval from the European Commission (EC) for the treatment of …
Complement Therapeutics’ geographic atrophy treatment receives FDA Fast Track designation
January 22, 2026Research and Development Complement Therapeutics, FDA, Opthalmology, geographic atrophy
Complement Therapeutics has announced that CTx001, its gene therapy treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD), …
PSI appoints David Allen as Country Manager for Canada
January 22, 2026Country Manager for Canada, PSI
PSI, a contract research organisation (CRO) with a focus on clinical trial delivery, has announced the appointment of David Allen …
Qureight appoints Steven Bishop as Chief Medical Officer
January 21, 2026Qureight, chief medical officer
Qureight has announced the appointment of Dr Steven Bishop as its new Chief Medical Officer (CMO). Bishop previously held the …
Pierre Fabre Laboratories and Iktos announce oncology collaboration
January 21, 2026Research and Development Iktos, Oncology, Pierre Fabre Laboratories
Pierre Fabre Laboratories and Iktos have announced a new collaboration intended to discover and develop new small-molecule drug candidates for …
Qureight appoints Rebecca Simmons as Chief Operating Officer
January 20, 2026Qureight, chief operating officer
Qureight has announced the appointment of Rebecca Simmons as Chief Operating Officer (COO). Simmons brings more than two decades of …
European Medicines Agency recommended 104 medicines for approval in 2025
January 20, 2026Research and Development European Medicines Agency, Rare Diseases
The European Medicines Agency (EMA) has announced data from 2025 showing that over the course of the year it recommended …
Spike in searches relating to spinal muscular atrophy following Jesy Nelson disclosure
January 19, 2026Medical Education Neurology, spinal muscular atrophy
New research from the Centre for Surgery has shown a significant rise in Google searches relating to spinal muscular atrophy …
Biogen’s high-dose Spinraza regimen receives European Commission approval for spinal muscular atrophy
January 19, 2026Research and Development Biogen, Neurology, Spinraza, spinal muscular atrophy
Biogen’s Spinraza (nusinersen) has received approval from the European Commission (EC) as a new high-dose regimen for the treatment of …
Alto Neuroscience announces new patent for depression treatment
January 15, 2026Sales and Marketing Alto Neuroscience, Psychiatry, depression
Alto Neuroscience, a clinical-stage biopharmaceutical company specialising in precision treatments for neuropsychiatric conditions, has announced the issuance of a US …
Arkin Capital closes $100m fund for pre-clinical and early clinical-stage biotech
January 15, 2026Sales and Marketing Arkin Capital, biotech
Arkin Capital has announced the closing of Arkin Bio Ventures III, a $100m fund designed to invest in pre-clinical and …
Bio-Sourcing and Zerion Pharma receive 1.3m euros in funding for joint breast cancer project
January 14, 2026Research and Development Bio-Sourcing, Oncology, Zerion Pharma, breast cancer
Bio-Sourcing and Zerion Pharma have announced that their collaboration to develop an oral form of the monoclonal antibody trastuzumab for …
Biocartis announces breast cancer research collaboration with US Mayo Clinic
January 14, 2026Research and Development Biocartis, Mayo Clinic, Oncology, breast cancer
Biocartis has announced a research collaboration with Mayo Clinic in the US, aiming to develop an accelerated sample-to-answer test resulting …
Blue Earth announces first UK patient received prostate cancer injection
January 13, 2026Research and Development Blue Earth Therapeutics, Oncology, prostate cancer
Blue Earth Therapeutics, a clinical-stage company specialising in targeted radiotherapeutics, has announced that the first UK patient has received its …
Medicus Pharma’s Teverelix shows positive efficacy and safety in premenopausal women
January 13, 2026Research and Development Endocrinology, Medicus Pharma, Teverelix
Medicus Pharma’s Teverelix has demonstrated long-lasting hormone suppression, as well as a favourable safety profile, in new study data. Teverelix …
PSI announces new Osaka office as part of Japanese expansion
January 12, 2026Sales and Marketing Osaka, PSI
PSI, a global contract research organisation (CRO), has announced the opening of a new office in Osaka as part of …
Teva’s Ajovy significantly reduces migraine in children and adolescents
January 12, 2026Research and Development Neurology, Teva, ajovy, migraine
Teva’s Ajovy (fremanezumab) has demonstrated significant reduction in monthly migraine and headache days in children and adolescents with episodic migraine …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
